DelveInsight’s, “Graves Ophthalmopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Graves Ophthalmopathy Understanding
Graves’ Ophthalmopathy: Overview
Graves’ ophthalmopathy, also called Graves’ orbitopathy or Thyroid-associated orbitopathy (TAO), is part of an autoimmune process that can affect the orbital and periorbital tissue, the thyroid gland, and, rarely, the pretibial skin or digits. Generally, occur in patients with hyperthyroidism or a history of hyperthyroidism. Risk factors for thyroid-associated orbitopathy include increased age of onset, duration of Graves’ hyperthyroidism, and smoking. The ocular manifestations of thyroid-associated orbitopathy include eyelid retraction, proptosis, chemosis, periorbital edema, and altered ocular motility with significant functional, social, and cosmetic consequences. The first step in treatment is to reverse the hyperthyroidism with either medication or surgery to remove the thyroid.
Graves’ ophthalmopathy- Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
• The companies and academics are working to assess challenges and seek opportunities that could influence Graves Ophthalmopathy R&D. The therapies under development are focused on novel approaches to treat/improve Graves Ophthalmopathy.
Graves Ophthalmopathy Emerging Drugs Chapters
This segment of the Graves Ophthalmopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Graves Ophthalmopathy Emerging Drugs
• Batoclimab (RVT-1401): Immunovant
FcRn is the primary protein responsible for preventing the degradation of IgG antibodies and albumin, the most abundant protein found in the blood. The role of FcRn is to bind to the IgG antibodies in the endosome, and transport them to the cell surface, where they are released back into circulation. RVT-1401 is designed to selectively bind to and inhibit FcRn, thus blocking the recycling of IgG antibodies. Currently, in phase 2 of clinical trials for the treatment of Graves Ophthalmopathy.
Further product details are provided in the report……..
Graves Ophthalmopathy: Therapeutic Assessment
This segment of the report provides insights about the different Graves Ophthalmopathy drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Graves Ophthalmopathy
There are approx. 3+ key companies which are developing the therapies for Graves Ophthalmopathy. The companies which have their Graves Ophthalmopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Immunovant and others.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Gene Therapy
• Monoclonal antibodies
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Graves Ophthalmopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Graves Ophthalmopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graves Ophthalmopathy drugs.
Graves Ophthalmopathy Report Insights
• Graves Ophthalmopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Graves Ophthalmopathy Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Graves Ophthalmopathy drugs?
• How many Graves Ophthalmopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graves Ophthalmopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Graves Ophthalmopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Graves Ophthalmopathy and their status?
• What are the key designations that have been granted to the emerging drugs?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook